Key features and details
- Rabbit polyclonal to BRCA2
- Suitable for: IP
- Reacts with: Human
- Isotype: IgG
Product nameAnti-BRCA2 antibody
See all BRCA2 primary antibodies
DescriptionRabbit polyclonal to BRCA2
Tested Applications & Species
Application Species IPHuman WBHuman
Synthetic peptide corresponding to Human BRCA2.
- Purchase matching WB positive control:Recombinant Human BRCA2 protein
- IP: HEK-293T cell lysate. WB: HEK293T, OVCAR-3, Hep-G2, K-562, Jurkat, HeLa, U2OS, and MCF-7 whole cell lysates.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7
Preservative: 0.09% Sodium azide
Constituents: 0.021% PBS, 1.764% Sodium citrate, 1.815% Tris
Concentration information loading...
PurityImmunogen affinity purified
Purification notesAntibodies were affinity purified using the peptide immobilized on solid support. Antibody concentration was determined by extinction coefficient: absorbance at 280 nmof 1.4 equals 1.0 mg of IgG.
- Epigenetics and Nuclear Signaling
- DNA / RNA
- DNA Damage & Repair
- DNA Damage Response
- BRCT Domain Proteins
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab9143 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Tested applications are guaranteed to work and covered by our Abpromise guarantee.
Predicted to work for this combination of applications and species but not guaranteed.
Does not work for this combination of applications and species.
Use a concentration of 1 - 4 µg/ml.
Use a concentration of 1 - 4 µg/ml.
FunctionInvolved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures.
Tissue specificityHighest levels of expression in breast and thymus, with slightly lower levels in lung, ovary and spleen.
Involvement in diseaseDefects in BRCA2 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.
Defects in BRCA2 are the cause of pancreatic cancer type 2 (PNCA2) [MIM:613347]. It is a malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.
Defects in BRCA2 are a cause of susceptibility to breast-ovarian cancer familial type 2 (BROVCA2) [MIM:612555]. A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate.
Defects in BRCA2 are the cause of Fanconi anemia complementation group D type 1 (FANCD1) [MIM:605724]. It is a disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair.
Defects in BRCA2 are a cause of glioma type 3 (GLM3) [MIM:613029]. Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.
Sequence similaritiesContains 8 BRCA2 repeats.
modificationsPhosphorylated by ATM upon irradiation-induced DNA damage.
Ubiquitinated in the absence of DNA damage; this does not lead to proteasomal degradation. In contrast, ubiquitination in response to DNA damage leads to proteasomal degradation.
- Information by UniProt
- BRCA 2 antibody
- BRCA1/BRCA2 containing complex subunit 2 antibody
- Brca2 antibody
All lanes : Anti-BRCA2 antibody (ab9143) at 0.1 µg/ml
Lane 1 : HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate
Lane 2 : OVCAR-3 (human ovary epithelial adenocarcinoma cell line) whole cell lysate
Lane 3 : HepG2 (human liver hepatocellular carcinoma cell line) whole cell lysate
Lane 4 : K562 (human chronic myelogenous leukemia cell line from bone marrow) whole cell lysate
Lane 5 : Jurkat (human T cell leukemia cell line from peripheral blood) whole cell lysate
Lane 6 : HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate
Lane 7 : U-2 OS (human bone osteosarcoma epithelial cell line) whole cell lysate
Lane 8 : MCF7 (human breast adenocarcinoma cell line) whole cell lysate
Lysates/proteins at 50 µg per lane.
Exposure time: 3 minutes
ab9143 immunoprecipitating BRCA2 at 6 µg per reaction.
Lane 1: ab9143 in HEK293T cell lysate.
Lane 2 (control): IgG control
For blotting, ab9143 immunoprecipitated BRAC2 at 0.1 µg/mL. Detected by Chemiluminescence.
ab9143 has been referenced in 5 publications.
- Hung LY et al. Microfluidic platforms for rapid screening of cancer affinity reagents by using tissue samples. Biomicrofluidics 12:054108 (2018). PubMed: 30344835
- Schaaf L et al. Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication Arrest. Cancer Res 76:2868-75 (2016). PubMed: 27013194
- Orthwein A et al. A mechanism for the suppression of homologous recombination in G1 cells. Nature 528:422-6 (2015). PubMed: 26649820
- Suzuki S et al. Inhibition of post-translational N-glycosylation by HRD1 that controls the fate of ABCG5/8 transporter. Sci Rep 4:4258 (2014). Human . PubMed: 24584735
- Hussain S et al. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1. Hum Mol Genet 12:2503-10 (2003). ICC/IF ; Human . PubMed: 12915460